Newsroom | 1893 results
Sorted by: Latest
-
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention...
-
ViiV Healthcare Commits $100 Million to Build More Resilient Local HIV Care Networks Across the United States
DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced a $100 million, three-year commitment through its U.S. Positive Action program, to provide sustained support to community organizations delivering HIV prevention and treatment services and advocacy; strengthen the navigators and referral networks that help people connect to and remain in care; and provide flexible funding to address emerging ga...
-
AHF Dedicates New Upland HIV Healthcare Center and Pharmacy
UPLAND, Calif.--(BUSINESS WIRE)--AHF Dedicates New Upland HIV Healthcare Center and Pharmacy...
-
Grindr Completes Acquisition of Freddie, Accelerating Grindr Health
WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced it has completed its acquisition of PurposeMed Inc., the parent company of Freddie, a leading telehealth provider of PrEP and HIV prevention care across the United States and Canada. The acquisition, first announced on September 30, 2026, brings Freddie and its partnerships with affiliated clinical networks into Grindr Health and establishes PrEP access as the foundation of...
-
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including late-brea...
-
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
RAHWAY, N.J.--(BUSINESS WIRE)--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN....
-
AHF Hails Introduction of Protect 340B Act of 2026
WASHINGTON--(BUSINESS WIRE)--AHF Hails Introduction of Protect 340B Act of 2026...
-
AHF Urges African Nations to Take Charge of Medicines Regulation
KIGALI, Rwanda--(BUSINESS WIRE)--With more than 20 African Union Member States yet to ratify the African Medicines Agency (AMA) Treaty, AIDS Healthcare Foundation (AHF) calls on African governments to accelerate ratification and regulatory harmonisation to expand access to affordable medicines and unlock Africa’s pharmaceutical manufacturing potential.The call comes as AMA convenes its inaugural week in Kigali, Rwanda, from 25–30 October 2026, against a backdrop of continued dependence on import...
-
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
KAMPALA, Uganda--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistent gaps in the HIV response. AHF’s work...
-
Gilead Sciences Announces Third Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026. “Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this qua...